SDHAF3: A Potential Drug Target for Psychiatric Disorders (G57001)

Target Name: SDHAF3

NCBI ID: G57001

SDHAF3

SDHAF3: A Potential Drug Target for Psychiatric Disorders

SDHAF3 (Sdh7) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the development and maintenance of the blood-brain barrier, which is a critical barrier that separates the brain from the surrounding tissue and helps to protect it from harmful substances.

Recent studies have identified SDHAF3 as a potential drug target for a variety of psychiatric and neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. This is because SDHAF3 is involved in the regulation of the formation of the blood-brain barrier, and the blood-brain barrier is thought to play a key role in the development of these disorders.

One of the reasons why SDHAF3 is considered a potential drug target is that it is involved in the regulation of the formation of the blood-brain barrier, which is a critical barrier that separates the brain from the surrounding tissue and helps to protect it from harmful substances. The blood-brain barrier is made up of several different components, including tight junctions, which are special cells that help to keep the brain separate from the surrounding tissue, and chaperone proteins, which help to transport and transport nutrients and waste products into and out of the brain.

Research has shown that changes in the expression of SDHAF3 can affect the formation of the blood-brain barrier, and that these changes may contribute to the development of psychiatric and neurological disorders. For example, studies have shown that mice that have been genetically modified to lack SDHAF3 have increased levels of harmful substances in their brains, such as beta-amyloid and neurofibrillary tangles, which are thought to contribute to the development of Alzheimer's disease.

In addition, SDHAF3 is also involved in the regulation of the penetration of nutrients and oxygen into the brain, and changes in the expression of SDHAF3 have been shown to affect the brain's ability to get the oxygen and nutrients it needs to function properly. This may be important for understanding the mechanisms of some psychiatric and neurological disorders, and may provide potential targets for new treatments.

Another potential reason why SDHAF3 is considered a drug target is that it is involved in the regulation of the production of other proteins that are important for brain function. For example, studies have shown that SDHAF3 is involved in the production of the protein PDGF-BB, which is a key regulator of cell growth and differentiation in the brain.

In addition, SDHAF3 is also involved in the regulation of the production of other proteins that are important for brain function. For example, studies have shown that SDHAF3 is involved in the production of the protein PDGF-BB, which is a key regulator of cell growth and differentiation in the brain.

In conclusion, SDHAF3 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the development and maintenance of the blood-brain barrier, and is involved in the regulation of the formation of the blood-brain barrier, the penetration of nutrients and oxygen into the brain, and the production of other proteins that are important for brain function. As a result, SDHAF3 is considered a potential drug target for a variety of psychiatric and neurological disorders.

Protein Name: Succinate Dehydrogenase Complex Assembly Factor 3

Functions: Plays an essential role in the assembly of succinate dehydrogenase (SDH), an enzyme complex (also referred to as respiratory complex II) that is a component of both the tricarboxylic acid (TCA) cycle and the mitochondrial electron transport chain, and which couples the oxidation of succinate to fumarate with the reduction of ubiquinone (coenzyme Q) to ubiquinol. Promotes maturation of the iron-sulfur protein subunit SDHB of the SDH catalytic dimer, protecting it from the deleterious effects of oxidants. May act together with SDHAF1

The "SDHAF3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDHAF3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets